David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Comcast
CMCSA
|
+$354M |
| 2 |
Wells Fargo
WFC
|
+$274M |
| 3 |
IBM
IBM
|
+$266M |
| 4 |
Qualcomm
QCOM
|
+$257M |
| 5 |
Mondelez International
MDLZ
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$356M |
| 2 |
PayPal
PYPL
|
+$290M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$261M |
| 4 |
NVIDIA
NVDA
|
+$248M |
| 5 |
AABA
Altaba Inc
AABA
|
+$245M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.31% |
| 2 | Healthcare | 10.66% |
| 3 | Consumer Discretionary | 10.29% |
| 4 | Communication Services | 8.78% |
| 5 | Financials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
PUT
Regeneron Pharmaceuticals
REGN
$85.9B
| $53.5M | 0.08% |
119,600
| – | – |
|
302
Navient
NAVI
$886M
| $53.5M | 0.08% |
3,559,837
+1,059,338
| +42% | +$15.4M |
|
|
CDK
303
DELISTED
CDK Global, Inc.
CDK
| $53.4M | 0.08% |
845,620
+232,739
| +38% | +$14.7M |
|
304
PUT
Teva Pharmaceuticals
TEVA
$43.5B
| $53M | 0.08% |
3,011,000
+1,183,500
| +65% | +$26.6M |
|
305
Citigroup
C
$221B
| $53M | 0.08% |
728,528
+579,898
| +390% | +$39.6M |
|
306
Wayfair
W
$13.9B
| $53M | 0.08% |
785,772
-408,307
| -34% | -$30.3M |
|
|
CTRA
307
DELISTED
Coterra Energy
CTRA
| $52.5M | 0.08% |
1,960,738
+294,238
| +18% | +$7.48M |
|
308
Salesforce
CRM
$171B
| $52.4M | 0.08% |
561,106
+334,475
| +148% | +$30.8M |
|
309
PUT
Morgan Stanley
MS
$336B
| $52.2M | 0.08% |
1,083,000
-24,000
| -2% | -$1.11M |
|
310
PUT
AT&T
T
$173B
| $51.9M | 0.08% |
1,752,844
-662,662
| -27% | -$18.8M |
|
|
WW
311
DELISTED
WW International
WW
| $51.8M | 0.08% |
1,189,910
+1,090,423
| +1,096% | +$45.3M |
|
312
Flex
FLEX
$40.8B
| $51.8M | 0.08% |
4,147,431
-468,929
| -10% | -$5.78M |
|
313
Carlisle Companies
CSL
$14.6B
| $51.7M | 0.08% |
515,555
-189,938
| -27% | -$18.4M |
|
314
Post Holdings
POST
$3.65B
| $51.6M | 0.08% |
893,779
+291,830
| +48% | +$16M |
|
|
ILG
315
DELISTED
ILG, Inc Common Stock
ILG
| $51.3M | 0.08% |
1,919,110
+267,264
| +16% | +$7.07M |
|
316
CALL
United Parcel Service
UPS
$86.8B
| $50.8M | 0.08% |
423,100
+9,900
| +2% | +$1.13M |
|
317
Exelixis
EXEL
$13.4B
| $50.2M | 0.08% |
2,073,686
-511,757
| -20% | -$13.6M |
|
318
Molson Coors Class B
TAP
$8.01B
| $49.5M | 0.08% |
606,109
-54,292
| -8% | -$4.78M |
|
319
PUT
ExxonMobil
XOM
$679B
| $49.3M | 0.08% |
601,700
+129,300
| +27% | +$10.3M |
|
320
Xcel Energy
XEL
$47.7B
| $49.3M | 0.08% |
1,041,426
+906,338
| +671% | +$43.5M |
|
321
Vertex Pharmaceuticals
VRTX
$139B
| $49.3M | 0.08% |
324,089
-484,897
| -60% | -$73M |
|
|
DVAX
322
DELISTED
Dynavax Technologies
DVAX
| $48.5M | 0.07% |
2,255,094
+1,515,150
| +205% | +$24M |
|
|
X
323
DELISTED
US Steel
X
| $48M | 0.07% |
1,872,097
+1,421,615
| +316% | +$34.8M |
|
|
VIAB
324
DELISTED
Viacom Inc. Class B
VIAB
| $47.9M | 0.07% |
1,720,916
+1,498,859
| +675% | +$46.2M |
|
|
BERY
325
DELISTED
Berry Global Group, Inc.
BERY
| $47.9M | 0.07% |
920,700
+416,479
| +83% | +$21.8M |
|
Similar funds
David Shaw's Q3 2017 Portfolio in Review
As of Q3 2017, David Shaw held 3,794 positions worth $65.1B, up 7.7% from $60.5B the previous quarter. Its ten largest holdings account for 9.6% of the portfolio.
David Shaw's Q3 2017 filing shows 469 new, 1,367 increased, 1,237 reduced and 370 closed positions. Its largest new stake was Baker Hughes: 3,076,914 shares worth $113M. The largest sale was Gilead Sciences, an estimated $356M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- David Shaw's largest Q3 2017 buy was Baker Hughes: 3,076,914 shares worth $113M.
- David Shaw added most to Comcast in Q3 2017, an estimated $354M increase.
- David Shaw's biggest Q3 2017 reduction was Gilead Sciences, cutting an estimated $356M.
- David Shaw fully exited Mobileye N.V. in Q3 2017, selling an estimated $72.4M.
- David Shaw's ten largest holdings make up 9.6% of its $65.1B portfolio in Q3 2017.
- David Shaw opened 469 new positions and closed 370 in Q3 2017.
- David Shaw's portfolio value rose 7.7% quarter-over-quarter to $65.1B.
Based on D.E. Shaw & Co's 13F filing for Q3 2017, filed 14 Nov 2017.